Core Insights - Tourmaline Bio, Inc. reported positive topline results from the Phase 2 TRANQUILITY trial of pacibekitug, indicating significant reductions in high-sensitivity C-reactive protein with quarterly dosing [1][6] - The company has a cash position of $256.4 million as of June 30, 2025, which is expected to fund operations into the second half of 2027 [1][9] Cardiovascular Inflammation Highlights - The TRANQUILITY trial demonstrated rapid, deep, and durable reductions in hs-CRP, achieving over 85% reduction from baseline in the 50 mg quarterly dosing arm after a single dose [6] - Pacibekitug is the first IL-6 inhibitor to show such results with quarterly dosing in a clinical trial, with statistical significance (p<0.0001) compared to placebo [6] Ongoing Development Activities - Tourmaline is on track to initiate a Phase 2 proof-of-concept trial in abdominal aortic aneurysm in the second half of 2025 [5][6] - Planning is underway for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease [5] Financial Results - Research and development expenses for Q2 2025 were $19.6 million, up from $15.7 million in Q2 2024, primarily due to increased clinical trial costs [13] - The net loss for Q2 2025 was $23.1 million, resulting in a net loss per share of $0.90, compared to a net loss of $17.5 million and a loss per share of $0.68 in Q2 2024 [13][19] Cash Position - As of June 30, 2025, cash, cash equivalents, and investments were $256.4 million, down from $294.9 million at the end of 2024 [9][21] - The current cash position is expected to support operations through key data readouts and development activities related to pacibekitug [9]